Back to Search
Start Over
Advances in pharmacotherapy for bronchiectasis in adults.
- Source :
-
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2023 Jun; Vol. 24 (9), pp. 1075-1089. Date of Electronic Publication: 2023 May 09. - Publication Year :
- 2023
-
Abstract
- Introduction: Bronchiectasis has become a growing concern of chronic airway disease because of the enormous socioeconomic burden. Four cardinal interdependent components - impaired airway defense, recurrent airway infections, inflammatory response, and airway damage, in conjunction with the underlying etiology, have collectively played a role in modulating the vicious vortex of the pathogenesis and progression of bronchiectasis. Current pharmacotherapy aims to target at these aspects to break the vicious vortex.<br />Areas Covered: The authors retrieve and review, in MEDLINE, Web of Science and ClinicalTrials.gov registry, the studies about pharmacotherapy for bronchiectasis from these aspects: antibiotics, mucoactive medications, bronchodilators, anti-inflammatory drug, and etiological treatment.<br />Expert Opinion: Future drug development and clinical trials of bronchiectasis need to pay more attention to the different phenotypes or endotypes of bronchiectasis. There is a need for the development of novel inhaled antibiotics that could reduce bacterial loads, improve quality-of-life, and decrease exacerbation risks. More efforts are needed to explore the next-generation neutrophil-targeted therapeutic drugs that are expected to ameliorate respiratory symptom burden, reduce exacerbation risks, and hinder airway destruction in bronchiectasis.
Details
- Language :
- English
- ISSN :
- 1744-7666
- Volume :
- 24
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Expert opinion on pharmacotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 37161410
- Full Text :
- https://doi.org/10.1080/14656566.2023.2210763